MENU

Trial Balance Internally Generated Income as of November 30, 2022

Trial Balance Regular Agency Fund as of November 30, 2022

Trial Balance Trust Receipt as of November 30, 2022

Trial Balance Business Type Income as of October 31, 2022

Trial Balance Internally Generated Income as of October 31, 2022

Trial Balance Regular Agency Fund as of October 31, 2022

Trial Balance Trust Receipt as of October 31, 2022

Trial Balance Business Type Income as of September 30, 2022

Trial Balance Internally Generated Income as of September 30, 2022

Trial Balance Regular Agency Fund as of September 30, 2022

Trial Balance Trust Receipt as of September 30, 2022

Statement of Changes in Net Assets/Equity Trust Receipt as of June 30, 2022

Statement of Changes in Net Assets/Equity Regular Agency Fund as of June 30, 2022

Statement of Changes in Net Assets/Equity Internally Generated Income as of June 30, 2022

Statement of Changes in Net Assets/Equity Business Type Income as of June 30, 2022

Trial Balance Trust Receipt as of June 30, 2022

Trial Balance Regular Agency Fund as of June 30, 2022

Trial Balance Internally Generated Income as of June 30, 2022

Trial Balance Business Type Income as of June 30, 2022

Detailed Statement of Financial Position Trust Receipt as of June 30, 2022

Detailed Statement of Financial Position Regular Agency Fund as of June 30, 2022

Detailed Statement of Financial Position Internally Generated Income as of June 30, 2022

Detailed Statement of Financial Position Business Type Income as of June 30, 2022

Detailed Statement of Financial Performance Trust Receipt for the period ending June 30, 2022

Detailed Statement of Financial Performance Regular Agency Fund for the Period ending June 30, 2022

Detailed Statement of Financial Performance Internally Generated For the Period ending June 30, 2022

Detailed Statement of Financial Performance Business Type Income For the period ending June 30, 2022

Detailed Statement of Cash Flows Trust Receipt for the Period June 01, 2022 to June 30, 2022

Detailed Statement of Cash Flows Regular Agency Fund For the Period June 01, 2022 to June 30, 2022

Detailed Statement of Cash Flows Internally Generated Income for the Period June 01, 2022 to June 30, 2022

Detailed Statement of Cash Flows Business Type Income for the Period June 01, 2022 to June 30, 2022

Condensed Statement of Financial Position Trust Receipt as of June 30, 2022

Condensed Statement of Financial Position Regular Agency Fund as of June 30, 2022

Condensed Statement of Financial Position Internally Generated Income as of June 30, 2022

Condensed Statement of Financial Position Business Type Income as of June 30, 2022

Condensed Statement of Financial Performance Trust Receipt for the Period ending June 30, 2022

Condensed Statement of Financial Performance Regular Agency Fund For the period ending June 30, 2022

Condensed Statement of Financial Performance Internally Generated Income for the Period ending June 30, 2022

Condensed Statement of Financial Performance Business Type Income for the Period ending June 30, 2022

Condensed Statement of Cash Flows Trust Receipt for the Period June 01, 2022 to June 30, 2022

Condensed Statement of Cash Flows Regular Agency Fund For the Period June 01, 2022 to June 30, 2022

Condensed Statement of Cash Flows Internally Generated Income for the Period June 01, 2022 to June 30, 2022

Condensed Statement of Cash Flows Business Type Income for the Period June 01, 2022 to June 30, 2022

Condensed Statement of Cash Flows Business Type Income for the Period June 01, 2022 to June 30, 2022

Trial Balance Business Type Income as of May 31, 2022

Trial Balance Initially Generated Income as of May 31, 2022

Trial Balance Regular Agency Fund as of May 31, 2022

Trial Balance Trust Receipt as of May 31, 2022

Agency Profile

Pre-Closing Trial Balance as of December 31, 2021 Business Type Income

Condensed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Drugs and Medicines Revolving Funds

Condensed Statement of Cash Flows December 31, 2021 Business Type Income

Condensed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Hospital Retained Income applicable to all DOH - retained hospitals - Hospital fees, medical/dental/laboratory fees, rent income from use of hospital equipment/facilities, proceeds sale of hospital products, devices, donations and other income - DOH-DOF-DBM J.C. 2003-1

Condensed Statement of Cash Flows for the period January 01, 2022 to March 31, 2022 Receipts Deposited with the National Treasury other than IAF

Condensed Statement of Cash Flows December 31, 2021 Initially Generated Income

Condensed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Internally Generated Income

Condensed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Specific Budgets of National Government Agencies

Condensed Statement of Cash Flows December 31, 2021 Regular Agency Fund

Condensed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Regular Agency Fund

Condensed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Receipts Deposited with Authorized Government Depository Banks (AGDB)

Condensed Statement of Cash Flows December 31, 2021 Trust Receipt

Condensed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Trust Receipt

Condensed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Business Type Income

Condensed Statement of Financial Performance for the Period ending December 31, 2021 Business Type Income

Condensed Statement of Financial Performance for the period ending March 31, 2022 Business Type Income

Condensed Statement of Financial Performance for the Period ending December 31, 2021 Internally Generated Income

Condensed Statement of Financial Performance For the period ending March 31, 2022 Internally Generated Income

Condensed Statement of Financial Performance December 31 2020 and 2021 Regular Agency Fund

Condensed Statement of Financial Performance For the period ending December 31, 2021 Regular Agency Fund

Condensed Statement of Financial Performance for the Period ending March 31, 2022 Regular Agency Fund

Condensed Statement of Financial Performance for the Period ending December 31, 2021 Trust Receipt

Condensed Statement of Financial Performance for the Period ending March 31, 2022 Trust Receipt

Condensed Statement of Financial Position Business Type Income 2020 and 2021

Condensed Statement of Financial Position As of December 31, 2021 Business Type Income

Condensed Statement of Financial Position as of March 31, 2022 Business Type Income

Condensed Statement of Financial Position Initially Generated Income

Condensed Statement of Financial Position As of December 31, 2021 Internally Generated Income

Condensed Statement of Financial Position As of March 31, 2022 Internally Generated Income

Condensed Statement of Financial Position Regular Agency Fund 2020 and 2021

Condensed Statement of Financial Position as of December 31, 2021 Regular Agency Fund

Condensed Statement of Financial Position as of March 31, 2022 Regular Agency Fund

Condensed Statement of Financial Position Trust Receipt

Condensed Statement of Financial Position as of December 31, 2021 Trust Receipt

Detailed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Receipts Deposited with the National Treasury other than IATF

Detailed Statement of Cash Flows December 31, 2021 Business Type Income

Detailed Statement of Cash Flows For the Period January 01, 2021 to December 31, 2021 Business Type Income

Detailed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321

Detailed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Hospital Retained Income applicable to all DOH - retained hospitals - Hospital fees, medical/dental/laboratory fees, rent income from use of hospital equipment/facilities, proceeds from sale of hospital products, devices, donations and other income - DOH-DOF-DBM J.C. 2003-1

Detailed Statement of Cash Flows December 31, 2021 Internally Generated Income

Detailed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Internally Generated Income

 Detailed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021

Detailed Statement of Cash Flows December 31, 2021 Regular Agency Fund

Detailed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Regular Agency Fund

Detailed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Receipts Deposited with Authorized Government Depository Banks (AGDB)

 Detailed Statement of Cash Flows for the Period January 01, 2022 to March 31, 2022 Specific Budgets of National Government Agencies

Detailed Statement of Cash Flows December 31, 2021 Trust Receipt

Detailed Statement of Cash Flows for the Period January 01, 2021 to December 31, 2021 Trust Receipt

Detailed Statement of Financial Performance December 31, 2020 and 2021

Detailed Statement of Financial Performance for the period ending December 31, 2021 Business Type Income

Detailed Statement of Financial Performance for the period ending March 31, 2022 Business Type Income

Detailed Statement of Financial Performance December 31, 2020 and 2021

Detailed Statement of Financial Performance As of December 31, 2021

Detailed Statement of Financial Performance December 31, 2020 and 2021

Detailed Statement of Financial Performance December 31, 2020 and 2021 Drugs and Medicines Revolving Funds - Drugs and Medicines - N.B.C. 321

Detailed Statement of Financial Performance For the period ending December 31, 2021 Internally Generated Income

Detailed Statement of Financial Performance For the Period ending March 31, 2022 Internally Generated Income

Detailed Statement of Financial Performance for the period ending December 31, 2021 Regular Agency Fund

Detailed Statement of Financial Performance for the Period ending March 31, 2022 Regular Agency Fund

Detailed Statement of Financial Performance December 31, 2020 and 2021 Specific Budgets of National Government Agencies

Detailed Statement of Financial Performance December 31, 2020 and 2021 Specific Budgets of National Government Agencies

Detailed Statement of Financial Performance December 31, 2020 and 2021 Trust Receipts Fund

Detailed Statement of Financial Performance For the period ending December 31, 2021 Trust Receipt

Detailed Statement of Financial Performance For the period ending March 31, 2022 Trust Receipt

Detailed Statement of Financial Position as of December 31, 2021 Business Type Income

Detailed Statement of Financial Position as of March 31, 2022 Business Type Income

Detailed Statement of Financial Position as of December 31, 2021

Detailed Statement of Financial Position as of December 31, 2021 Internally Generated Income

Detailed Statement of Financial Position as of March 31, 2022 Internally Generated Income

Detailed Statement of Financial Position as of December 31, 2021 Regular Agency Fund

Detailed Statement of Financial Position as of March 31, 2022 Regular Agency Fund

Detailed Statement of Financial Position as of December 31, 2021 Trust Receipt

Detailed Statement of Financial Position as of March 31, 2022 Trust Receipt

Post-Closing Trial Balance as of December 31, 2021 Business Type Income

Post-Closing Trial Balance as of December 31, 2021 Internally Generated Income

Post-Closing Trial Balance as of December 31, 2021 Regular Agency Fund

Post-Closing Trial Balance as of December 31, 2021 Regular Agency Fund

Post-Closing Trial Balance as of December 31, 2021 Trust Receipt

Pre-Closing Trial Balance as of December 31, 2021 Regular Agency Fund

Pre-Closing Trial Balance as of December 31, 2021 Internally Generated Income

Pre-Closing Trial Balance as of December 31, 2021 Trust Receipt

Pre-Closing Trial Balance as of December 31, 2021 Regular Agency Fund

Statement of Changes in Net Assets/Equity as of March 31, 2022 Business Type Income

Statement of Changes in Net Assets/Equity as of December 31, 2021 Internally Generated Income

Statement of Changes in Net Asset/Equity as of March 31, 2022 Internally Generated Income

Statement of Changes in Net Assets/Equity as of December 31, 2021 Regular Agency Fund

Statement of Changes in Net Assets/Equity as of March 31, 2022 Regular Agency Fund

Statement of Changes in Net Assets/Equity as of December 31, 2021 Trust Receipt

Statement of Changes in Net Assets/Equity as of March 31, 2022 Trust Receipt

Statement of Changes in Net Assets/Equity as of December 31, 2021 Business Type Income

Trial Balance as of April 30, 2022 Business Type Income

Trial Balance as of February 28, 2022 Business Type Income

Trial Balance as of January 31, 2022 Business Type Income

Trial Balance as of March 31, 2022 Business Type Income

Trial Balance as of April 30, 2022 Internally Generated Income

Trial Balance as of February 28, 2022 Internally Generated Income

Trial Balance as of January 31, 2022 Internally Generated Income

Trial Balance as of March 31, 2022 Internally Generated Income

Trial Balance as of April 30, 2022 Regular Agency Fund

Trial Balance as of February 28, 2022 Regular Agency Fund

Trial Balance as of January 31, 2022 Regular Agency Fund

Trial Balance as of March 31, 2022 Regular Agency Fund

Trial Balance as of April 30, 2022 Trust Receipt

Trial Balance as of February 28, 2022 Trust Receipt

Trial Balance as of January 31, 2022 Trust Receipt

Trial Balance as of March 31, 2022 Trust Receipt